Drugs / RH5.2 VLP
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05357560 | Jul 2023 → Dec 2025 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05978037 Comparator | Aug 2023 → Apr 2026 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RH5.2-VLP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05978037 ↗ |
| Modality | Vaccine | “blood-stage vaccine candidate RH5.2 Virus-like Particle (VLP)” NCT05357560 ↗ |